This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): SB-921
Description: SB-743921 is a novel small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin protein essential for proper cell division.
Deal Structure: SB-743921 is the second drug candidate in clinical development that has arisen from a strategic collaboration between Cytokinetics and GSK to discover, develop and commercialize novel small molecule therapeutics targeting human mitotic kinesins for applications in the treatment of cancer and other diseases.
In September 2005, Cytokinetics announced theamendment of the company's strategic alliance with GSK, which provides Cytokinetics an expanded role in clinical research and development for SB-743921.
Under the terms of the amendment, Cytokinetics will lead and fund development activities to explore the potential application of SB-743921 in certain indications, subject to the option for GSK to resume responsibility for development and commercialization activities for SB-743921 for these indications during a defined period. Cytokinetics' development activities will be conducted in parallel with GSK's conduct of development activities for SB-743921 in other indications.
Additional information available to subscribers only: